Rallybio Corp (RLYB) stock
RLYBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/30
$15.29−0.14 (-0.88%)
Close on Nov 17, 2026Market cap $82.32MP/E 3.4Yield –
Rallybio total assets
Total assets on the balance sheet at the end of each period.
Rallybio's total assets was $95.58M at Sep 30, 2026. For fiscal 2025 it was $62.26M, down 8.6% from the year before. The highest annual figure on record is $182.19M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $62.26M | -8.6% |
| FY2024 | Dec 31, 2024 | $68.11M | -41.1% |
| FY2023 | Dec 31, 2023 | $115.62M | -35.9% |
| FY2022 | Dec 31, 2022 | $180.44M | -1.0% |
| FY2021 | Dec 31, 2021 | $182.19M | +28.4% |
| FY2020 | Dec 31, 2020 | $141.86M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $95.58M | +41.3% |
| Q2 FY2026 | Jun 30, 2026 | $98.06M | +92.3% |
| Q1 FY2026 | Mar 31, 2026 | $54.47M | -6.1% |
| Q4 FY2025 | Dec 31, 2025 | $62.26M | -8.6% |
| Q3 FY2025 | Sep 30, 2025 | $67.66M | -14.4% |
| Q2 FY2025 | Jun 30, 2025 | $51.00M | -44.8% |
| Q1 FY2025 | Mar 31, 2025 | $57.98M | -41.6% |
| Q4 FY2024 | Dec 31, 2024 | $68.11M | -41.1% |
| Q3 FY2024 | Sep 30, 2024 | $79.01M | -40.7% |
| Q2 FY2024 | Jun 30, 2024 | $92.43M | -37.4% |
| Q1 FY2024 | Mar 31, 2024 | $99.36M | -38.8% |
| Q4 FY2023 | Dec 31, 2023 | $115.62M | -35.9% |
| Q3 FY2023 | Sep 30, 2023 | $133.19M | -7.3% |
| Q2 FY2023 | Jun 30, 2023 | $147.58M | -5.2% |
| Q1 FY2023 | Mar 31, 2023 | $162.32M | -4.2% |
| Q4 FY2022 | Dec 31, 2022 | $180.44M | -1.0% |
| Q3 FY2022 | Sep 30, 2022 | $143.67M | -25.9% |
| Q2 FY2022 | Jun 30, 2022 | $155.61M | +29.6% |
| Q1 FY2022 | Mar 31, 2022 | $169.35M | +19.4% |
| Q4 FY2021 | Dec 31, 2021 | $182.19M | – |
| Q3 FY2021 | Sep 30, 2021 | $193.87M | – |
| Q2 FY2021 | Jun 30, 2021 | $120.10M | – |
| Q4 FY2020 | Dec 31, 2020 | $141.86M | – |
See a number that looks wrong?